Uncomplicated acute appendicitis
Conditions
Brief summary
The primary endpoint of the APPAC II trial is defined as the success of the randomised treatment at one-year follow-up (treatment efficacy). Treatment success in both groups is defined as the resolution of acute appendicitis with antibiotic treatment resulting in discharge from the hospital without the need for surgical intervention and no recurrent appendicitis during a follow-up of one year.
Detailed description
Secondary endpoints include post-intervention complications (possible postoperative complications classified using the Clavien-Dindo classification), late recurrence (after one year) of acute appendicitis after antibiotic treatment, duration of hospital stay, VAS scores, quality of life (QOL, using for example 5D or 15D validated QOL questionnaire), length of sick leave and treatment costs.
Interventions
DRUGLEVOFLOXACIN
DRUGERTAPENEM
DRUGMOXIFLOXACIN
DRUGMETRONIDAZOLE
Sponsors
Turku University Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of the APPAC II trial is defined as the success of the randomised treatment at one-year follow-up (treatment efficacy). Treatment success in both groups is defined as the resolution of acute appendicitis with antibiotic treatment resulting in discharge from the hospital without the need for surgical intervention and no recurrent appendicitis during a follow-up of one year. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints include post-intervention complications (possible postoperative complications classified using the Clavien-Dindo classification), late recurrence (after one year) of acute appendicitis after antibiotic treatment, duration of hospital stay, VAS scores, quality of life (QOL, using for example 5D or 15D validated QOL questionnaire), length of sick leave and treatment costs. | — |
Countries
Finland
Outcome results
None listed